{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T23:13:37Z","timestamp":1762125217245,"version":"3.37.3"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T00:00:00Z","timestamp":1567728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T00:00:00Z","timestamp":1567728000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Warfarin is a widely used anticoagulant with a narrow therapeutic index and large interpatient variability in the therapeutic dose. Complications from inappropriate warfarin dosing are one of the most common reasons for emergency room visits. Approximately one third of warfarin dose variability results from common genetic variants. Therefore, it is very necessary to recognize warfarin sensitivity in individuals caused by genetic variants. Based on combined polymorphisms in <jats:italic>CYP2C9<\/jats:italic> and <jats:italic>VKORC1<\/jats:italic>, we established a clinical classification for warfarin sensitivity. In the International Warfarin Pharmacogenetic Consortium (IWPC) with 5542 patients, we found that 95.1% of the Black in the IWPC cohort were normal warfarin responders, while 74.8% of the Asian were warfarin sensitive (P\u2009&lt;\u20090.001). Moreover, we created a clinical algorithm to predict warfarin sensitivity in individual patients using logistic regression. Compared to a fixed-dose approach, the clinical algorithm provided significantly better performance. In addition, we validated the derived clinical algorithm using the external Easton cohort with 106 chronic warfarin users. The AUC was 0.836 vs. 0.867 for the Easton cohort and the IWPC cohort, respectively. With the use of this algorithm, it is very likely to facilitate patient care regarding warfarin therapy, thereby improving clinical outcomes.<\/jats:p>","DOI":"10.1038\/s41598-019-49329-0","type":"journal-article","created":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T13:22:00Z","timestamp":1567776120000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Clinical Model for Predicting Warfarin Sensitivity"],"prefix":"10.1038","volume":"9","author":[{"given":"Zhiyuan","family":"Ma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8312-4599","authenticated-orcid":false,"given":"Gang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bahar","family":"Khalighi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koroush","family":"Khalighi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,9,6]]},"reference":[{"key":"49329_CR1","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1161\/CIRCULATIONAHA.112.100628","volume":"125","author":"JA Johnson","year":"2012","unstructured":"Johnson, J. A. Warfarin pharmacogenetics: a rising tide for its clinical value. Circulation 125, 1964\u20131966 (2012).","journal-title":"Circulation"},{"key":"49329_CR2","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1016\/j.amjmed.2015.05.044","volume":"128","author":"GD Barnes","year":"2015","unstructured":"Barnes, G. D., Lucas, E., Alexander, G. C. & Goldberger, Z. D. National Trends in Ambulatory Oral Anticoagulant Use. Am J Med 128, 1300\u20131305 e1302 (2015).","journal-title":"Am J Med"},{"key":"49329_CR3","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1097\/FTD.0000000000000192","volume":"37","author":"K Shaw","year":"2015","unstructured":"Shaw, K. et al. Clinical Practice Recommendations on Genetic Testing of CYP2C9 and VKORC1 Variants in Warfarin Therapy. Ther Drug Monit 37, 428\u2013436 (2015).","journal-title":"Ther Drug Monit"},{"key":"49329_CR4","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1182\/blood-2004-06-2111","volume":"105","author":"G D\u2019Andrea","year":"2005","unstructured":"D\u2019Andrea, G. et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 105, 645\u2013649 (2005).","journal-title":"Blood"},{"key":"49329_CR5","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1056\/NEJMoa044503","volume":"352","author":"MJ Rieder","year":"2005","unstructured":"Rieder, M. J. et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 352, 2285\u20132293 (2005).","journal-title":"N Engl J Med"},{"key":"49329_CR6","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1160\/TH04-02-0083","volume":"91","author":"HV Joffe","year":"2004","unstructured":"Joffe, H. V. et al. Warfarin dosing and cytochrome P450 2C9 polymorphisms. Thromb Haemost 91, 1123\u20131128 (2004).","journal-title":"Thromb Haemost"},{"key":"49329_CR7","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.clpt.2006.04.006","volume":"80","author":"T Schalekamp","year":"2006","unstructured":"Schalekamp, T. et al. VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation. Clin Pharmacol Ther 80, 13\u201322 (2006).","journal-title":"Clin Pharmacol Ther"},{"key":"49329_CR8","unstructured":"US Food and Drug Administration. Warfarin (coumadin) product labeling, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/009218s107lbl.pdf. Accessed May 28, 2018, (Accessed May 28, 2018)."},{"key":"49329_CR9","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1056\/NEJMoa0809329","volume":"360","author":"International Warfarin Pharmacogenetics, C.","year":"2009","unstructured":"International Warfarin Pharmacogenetics, C. et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 360, 753\u2013764 (2009).","journal-title":"N Engl J Med"},{"key":"49329_CR10","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/clpt.2010.13","volume":"87","author":"P Lenzini","year":"2010","unstructured":"Lenzini, P. et al. Integration of genetic, clinical, and INR data to refine warfarin dosing. Clin Pharmacol Ther 87, 572\u2013578 (2010).","journal-title":"Clin Pharmacol Ther"},{"key":"49329_CR11","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2217\/pgs.13.212","volume":"15","author":"E Grossi","year":"2014","unstructured":"Grossi, E. et al. Prediction of optimal warfarin maintenance dose using advanced artificial neural networks. Pharmacogenomics 15, 29\u201337 (2014).","journal-title":"Pharmacogenomics"},{"key":"49329_CR12","doi-asserted-by":"publisher","first-page":"e0205872","DOI":"10.1371\/journal.pone.0205872","volume":"13","author":"Z Ma","year":"2018","unstructured":"Ma, Z., Wang, P., Gao, Z., Wang, R. & Khalighi, K. Ensemble of machine learning algorithms using the stacked generalization approach to estimate the warfarin dose. PLoS One 13, e0205872 (2018).","journal-title":"PLoS One"},{"key":"49329_CR13","doi-asserted-by":"publisher","first-page":"3827","DOI":"10.1182\/blood-2009-12-255992","volume":"115","author":"NA Limdi","year":"2010","unstructured":"Limdi, N. A. et al. Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood 115, 3827\u20133834 (2010).","journal-title":"Blood"},{"key":"49329_CR14","doi-asserted-by":"publisher","first-page":"22S","DOI":"10.1378\/chest.119.1_suppl.22S","volume":"119","author":"J Ansell","year":"2001","unstructured":"Ansell, J. et al. Managing oral anticoagulant therapy. Chest 119, 22S\u201338S (2001).","journal-title":"Chest"},{"key":"49329_CR15","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1038\/clpt.2010.322","volume":"89","author":"MA Perera","year":"2011","unstructured":"Perera, M. A. et al. The missing association: sequencing-based discovery of novel SNPs in VKORC1 and CYP2C9 that affect warfarin dose in African Americans. Clin Pharmacol Ther 89, 408\u2013415 (2011).","journal-title":"Clin Pharmacol Ther"},{"key":"49329_CR16","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/clpt.2009.223","volume":"87","author":"LH Cavallari","year":"2010","unstructured":"Cavallari, L. H. et al. Genetic and clinical predictors of warfarin dose requirements in African Americans. Clin Pharmacol Ther 87, 459\u2013464 (2010).","journal-title":"Clin Pharmacol Ther"},{"key":"49329_CR17","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/j.1365-2141.2012.09150.x","volume":"158","author":"K Lund","year":"2012","unstructured":"Lund, K. et al. Polymorphisms in VKORC1 have more impact than CYP2C9 polymorphisms on early warfarin International Normalized Ratio control and bleeding rates. Br J Haematol 158, 256\u2013261 (2012).","journal-title":"Br J Haematol"},{"key":"49329_CR18","doi-asserted-by":"publisher","unstructured":"Ravvaz, K., Weissert, J. A., Ruff, C. T., Chi, C. L. & Tonellato, P. J. Personalized Anticoagulation: Optimizing Warfarin Management Using Genetics and Simulated Clinical Trials. Circ Cardiovasc Genet 10, https:\/\/doi.org\/10.1161\/CIRCGENETICS.117.001804 (2017).","DOI":"10.1161\/CIRCGENETICS.117.001804"},{"key":"49329_CR19","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1111\/jth.13014","volume":"13","author":"S Abohelaika","year":"2015","unstructured":"Abohelaika, S., Wynne, H., Avery, P. & Kamali, F. Influence of CYP2C9 polymorphism on the fall in International Normalized Ratio in patients interrupting warfarin therapy before elective surgery. J Thromb Haemost 13, 1436\u20131440 (2015).","journal-title":"J Thromb Haemost"},{"key":"49329_CR20","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1056\/NEJMoa1310669","volume":"369","author":"SE Kimmel","year":"2013","unstructured":"Kimmel, S. E. et al. A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med 369, 2283\u20132293 (2013).","journal-title":"N Engl J Med"},{"key":"49329_CR21","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1161\/CIRCULATIONAHA.111.070920","volume":"125","author":"JL Anderson","year":"2012","unstructured":"Anderson, J. L. et al. A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II). Circulation 125, 1997\u20132005 (2012).","journal-title":"Circulation"},{"key":"49329_CR22","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1001\/jama.2017.11469","volume":"318","author":"BF Gage","year":"2017","unstructured":"Gage, B. F. et al. Effect of Genotype-Guided Warfarin Dosing on Clinical Events and Anticoagulation Control Among Patients Undergoing Hip or Knee Arthroplasty: The GIFT Randomized Clinical Trial. JAMA 318, 1115\u20131124 (2017).","journal-title":"JAMA"},{"key":"49329_CR23","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/nature02214","volume":"427","author":"S Rost","year":"2004","unstructured":"Rost, S. et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 427, 537\u2013541 (2004).","journal-title":"Nature"},{"key":"49329_CR24","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.ajhg.2007.10.002","volume":"82","author":"SA Scott","year":"2008","unstructured":"Scott, S. A., Edelmann, L., Kornreich, R. & Desnick, R. J. Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations. Am J Hum Genet 82, 495\u2013500 (2008).","journal-title":"Am J Hum Genet"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-49329-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-49329-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-49329-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T13:17:15Z","timestamp":1671283035000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-49329-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,6]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["49329"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-49329-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2019,9,6]]},"assertion":[{"value":"19 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"12856"}}